Shareholder Rights Law Firm Johnson & Weaver, LLP Initiates Investigations of; NewLink Genetics Corporation, DeVry Education Group, Inc., Target Corporation, La Quinta Holdings Inc and Carbylan Therap

Shareholder Rights Law Firm Johnson & Weaver, LLP Initiates Investigations of; NewLink Genetics Corporation, DeVry Education Group, Inc., Target Corporation, La Quinta Holdings Inc and Carbylan Therapeutics, Inc.; Encourages Investors to Contact the Firm for Information Concerning Their Legal Rights

PR Newswire

SAN DIEGO, May 20, 2016 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential claims against NewLink Genetics Corporation, DeVry Education Group, Inc., Target Corporation, La Quinta Holdings Inc. and Carbylan Therapeutics, Inc., as detailed below:

Johnson & Weaver LLP

NewLink Genetics Corporation 

Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by NewLink Genetics Corporation (NASDAQ: NLNK) and certain of its officers. A class action lawsuit against the Company has been filed on behalf of shareholders who purchased NewLink betweenSeptember 17, 2013 and May 9, 2016, (the "Class Period").

The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about NewLink's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company's algenpantucel-L treatment was ineffective and potentially harmful to patients; and (ii) as a result of the foregoing, NewLink's public statements were materially false and misleading at all relevant times. 

On May 9, 2016, post-market, NewLink announced that algenpantucel-L did not meet the main goal in the Company's Phase 3 IMPRESS study.  Patients treated with algenpantucel-L lived for a median of 27.3 months in NewLink's Phase 3 trial, compared to median survival of 30.4 months for patients treated with standard therapy, suggesting that patients were actually harmed by NewLink's treatment.

On this news, NewLink's stock price dropped 30.61%, to close at $11.45 on May 10, 2016.

If you have held shares continuously prior to September 2013, you may have standing to hold NewLink harmless from the damage the officers and directors caused by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.

If you are a NewLink shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.

DeVry Education Group, Inc.

Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by DeVry Education Group, Inc. (NYSE: DV) and certain of its officers. A class action lawsuit against the Company has been filed on behalf of shareholders who purchased DeVry between February 4, 2011 and January 27, 2016. (the "Class Period").

The Complaint alleges that DeVry failed to disclose that: (1) the Company was involved in a prolonged deceptive advertising campaign; and (2) DeVry exaggerated its students' ability to secure jobs after graduation.

If you have held shares continuously prior to February 2011, you may have standing to hold DeVry harmless from the damage the officers and directors caused by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.

If you are a DeVry shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.

Target Corporation

Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Target Corporation (NYSE: TGT) and certain of its officers. A class action lawsuit against the Company has been filed on behalf of shareholders who purchased Target between February 27, 2013 and May 19, 2014, (the "Class Period").

The complaint alleges that throughout the Class Period, Target issued false and misleading statements to investors and failed to disclose that: (1) at the time of the opening of Target's first group of stores in Canada, Target had significant problems with its supply chain infrastructure, distribution centers, and technology systems, as well as inadequately trained employees; (2) these problems caused significant, pervasive issues, including excess inventory at distribution centers and inadequate inventory at retail locations; (3) the excess inventory at distribution centers and lack of inventory at retail locations forced Target to heavily discount products and incur heavy losses; and (4) the supply-chain and personnel problems were not typical of newly launched locations in Target's traditional U.S.-based market; and (5) as a result, Target's public statements were materially false and misleading at all relevant times. When the true details were known, the lawsuit claims that investors suffered damages.

If you have held shares continuously prior to February 2013, you may have standing to hold Target harmless from the damage the officers and directors caused by making them personally responsible. You may also be able to assist in reforming the Company's corporate governance to prevent future wrongdoing.

If you are a Target shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.

La Quinta Holdings Inc.

Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by La Quinta Holdings Inc (NYSE: LQ) and certain of its officers. A class action lawsuit against the Company has been filed on behalf of shareholders who purchased La Quinta between February 25, 2015 and September 17, 2015, (the "Class Period").

The complaint alleges throughout the Class Period La Quinta issued false and misleading statements to investors and failed to disclose that: (1) La Quinta was experiencing declining customer demand in its key Texas market; (2) there were on-going disruptions caused by the transitioning of La Quinta's call center operations; (3) La Quinta was experiencing declining customer demand and market share losses due in part to certain of La Quinta's facilities being outdated and in need of major renovation, thus necessitating significant capital expenditures and operational disruptions; and (4) as a result, La Quinta's public statements were materially false and misleading. When the true details entered the market, the lawsuit claims that investors suffered damages.

If you are a La Quinta shareholder and are interested in learning more about the investigation or your legal rights and remedies, please contact lead analyst Jim Baker ([email protected]) at 619-814-4471. If you email, please include your phone number.

Carbylan Therapeutics, Inc.

Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Carbylan Therapeutics, Inc. (NASDAQ: CBYL) and certain of its officers in connection with the Company's initial public offering (IPO). Specifically, Johnson & Weaver's investigation seeks to determine whether certain statements regarding the Company's business metrics and financial prospects were not as strong as represented in the Registration Statement.

On May 12, 2016 the Company reported net losses of approximately $6.6 million and $5.2 million in the three months ended March 31, 2016 and 2015, respectively.

If you have information that could assist in this investigation, or if you are a Carbylan shareholder who suffered a loss on that investment and are interested in learning more about the investigation or your legal rights and remedies, please contact Jim Baker ([email protected]) by email or by phone at 619-814-4471. If emailing, please include a phone number where you can be reached.

About Johnson & Weaver, LLP:

Johnson & Weaver, LLP is a nationally recognized shareholder rights law firm with offices in California, New York and Georgia. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits. For more information about the firm and its attorneys, please visit http://www.johnsonandweaver.com. Attorney advertising. Past results do not guarantee future outcomes.

Contact:

Johnson & Weaver, LLP
Jim Baker, 619-814-4471
[email protected]

Logo - http://photos.prnewswire.com/prnh/20160211/332409LOGO

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-rights-law-firm-johnson--weaver-llp-initiates-investigations-of-newlink-genetics-corporation-devry-education-group-inc-target-corporation-la-quinta-holdings-inc-and-carbylan-therapeutics-inc-encourages-inves-300272674.html

SOURCE Johnson & Weaver, LLP

Copyright CNW Group 2016